EGFR and cancer: LC17 CAFs also protected the corresponding cancer cells carrying EGFR mutations and contributed to EGFR-targeted drug (osimertinib) resistance in LCAs (Supplementary Fig. 8c, d; Supplementary Table 2), which was consistent with CAF-driven EGFR inhibitor resistance49,53.